Geron Past Earnings Performance
Past criteria checks 0/6
Geron's earnings have been declining at an average annual rate of -27.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 8.9% per year.
Key information
-27.2%
Earnings growth rate
-3.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 8.9% |
Return on equity | -71.6% |
Net Margin | -15,990.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued
Dec 20Geron: A Major Catalyst For Shareholders Arrives In January - At Last
Sep 16Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?
Sep 14Geron rises on narrower-than-expected Q2 loss
Aug 12Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt
Aug 05Geron: Waiting For Godot
Jul 15Geron: TLR Is 10 Months Away
May 03Revenue & Expenses Breakdown
How Geron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1 | -220 | 108 | 0 |
31 Mar 24 | 1 | -201 | 85 | 0 |
31 Dec 23 | 0 | -184 | 70 | 0 |
30 Sep 23 | 0 | -175 | 70 | 0 |
30 Jun 23 | 0 | -171 | 60 | 0 |
31 Mar 23 | 0 | -150 | 51 | 0 |
31 Dec 22 | 1 | -142 | 45 | 0 |
30 Sep 22 | 2 | -131 | 32 | 0 |
30 Jun 22 | 1 | -117 | 30 | 0 |
31 Mar 22 | 1 | -118 | 30 | 0 |
31 Dec 21 | 1 | -116 | 31 | 0 |
30 Sep 21 | 0 | -108 | 30 | 0 |
30 Jun 21 | 0 | -101 | 30 | 0 |
31 Mar 21 | 0 | -87 | 28 | -4 |
31 Dec 20 | 0 | -76 | 27 | 0 |
30 Sep 20 | 0 | -81 | 25 | 0 |
30 Jun 20 | 0 | -76 | 23 | 0 |
31 Mar 20 | 0 | -75 | 22 | 2 |
31 Dec 19 | 0 | -69 | 22 | 0 |
30 Sep 19 | 1 | -47 | 21 | 1 |
30 Jun 19 | 1 | -37 | 20 | 2 |
31 Mar 19 | 1 | -30 | 19 | 5 |
31 Dec 18 | 1 | -27 | 19 | 0 |
30 Sep 18 | 1 | -27 | 19 | 3 |
30 Jun 18 | 1 | -28 | 20 | 2 |
31 Mar 18 | 1 | -28 | 20 | 2 |
31 Dec 17 | 1 | -28 | 19 | 3 |
30 Sep 17 | 1 | -29 | 19 | 3 |
30 Jun 17 | 6 | -26 | 18 | 3 |
31 Mar 17 | 6 | -28 | 19 | 3 |
31 Dec 16 | 6 | -30 | 19 | 3 |
30 Sep 16 | 6 | -30 | 19 | 4 |
30 Jun 16 | 37 | 1 | 19 | 5 |
31 Mar 16 | 37 | 1 | 18 | 6 |
31 Dec 15 | 36 | 0 | 18 | 8 |
30 Sep 15 | 36 | 0 | 18 | 10 |
30 Jun 15 | 1 | -37 | 17 | 11 |
31 Mar 15 | 1 | -37 | 17 | 12 |
31 Dec 14 | 1 | -36 | 17 | 12 |
30 Sep 14 | 1 | -36 | 16 | 12 |
30 Jun 14 | 1 | -35 | 15 | 12 |
31 Mar 14 | 1 | -35 | 15 | 12 |
31 Dec 13 | 1 | -38 | 16 | 14 |
30 Sep 13 | 2 | -45 | 16 | 18 |
Quality Earnings: GERN is currently unprofitable.
Growing Profit Margin: GERN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of 27.2% per year.
Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: GERN has a negative Return on Equity (-71.59%), as it is currently unprofitable.